Memantine Dosing with CrCl 34 mL/min
For a patient with a creatinine clearance of 34 mL/min, use the standard memantine dosing regimen with a target dose of 10 mg twice daily (20 mg/day total), as no dose adjustment is required for moderate renal impairment.
Rationale Based on FDA Labeling
The FDA prescribing information clearly specifies that dose reduction is only necessary for severe renal impairment (CrCl 5-29 mL/min), where the target dose should be reduced to 5 mg twice daily 1. Your patient with CrCl 34 mL/min falls into the moderate renal impairment category (CrCl 30-49 mL/min), which does not require dose adjustment according to the official drug label.
Standard Titration Schedule
Start with 5 mg once daily and titrate as follows 1:
- Week 1: 5 mg once daily
- Week 2: 5 mg twice daily (10 mg/day)
- Week 3: 15 mg/day (5 mg in morning, 10 mg in evening)
- Week 4 onward: 10 mg twice daily (20 mg/day target dose)
Allow at least one week between dose increases.
Supporting Pharmacokinetic Evidence
Research data support this FDA recommendation. A pharmacokinetic study demonstrated that patients with moderate renal impairment (CrCl 30-49 mL/min) had a 60% increase in drug exposure compared to those with normal renal function, but steady-state simulations predicted maximum concentrations of 128 ng/mL with standard 10 mg twice daily dosing—well within the therapeutic range 2. Only patients with severe renal impairment (CrCl 5-29 mL/min) showed a 115% increase in exposure, necessitating dose reduction to 5 mg twice daily to maintain safe plasma levels around 84 ng/mL 2.
Important Clinical Caveats
- Monitor for adverse effects: Patients with moderate renal impairment have increased drug exposure, so watch for dizziness, confusion, headache, or constipation 1
- Avoid alkalinizing agents: Conditions that raise urine pH decrease memantine elimination and can increase plasma levels 1
- Body weight matters: Lower body weight patients may have higher drug exposure; consider this if adverse effects emerge 3
- If dosing is interrupted: Resume at lower doses and retitrate if the patient misses several days of medication 1
The consensus guideline from geriatric clinical pharmacists supports specific dose adjustments for memantine in renal impairment, though it does not provide the granular CrCl cutoffs that the FDA label does 4.